TCGA-CN-6022-01A-21R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.064155251
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- ANGIOGENESIS+0.420
- HEDGEHOG_SIGNALING+0.380
- MITOTIC_SPINDLE+0.340
- TGF_BETA_SIGNALING+0.340
- WNT_BETA_CATENIN_SIGNALING+0.320
- APICAL_JUNCTION+0.310
- UV_RESPONSE_DN+0.270
- INFLAMMATORY_RESPONSE+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- OXIDATIVE_PHOSPHORYLATION-0.460
- INTERFERON_GAMMA_RESPONSE-0.410
- FATTY_ACID_METABOLISM-0.320
- CHOLESTEROL_HOMEOSTASIS-0.260
- ESTROGEN_RESPONSE_LATE-0.210
- HEME_METABOLISM-0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
- P53_PATHWAY-0.170
- BILE_ACID_METABOLISM-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-6989-01A-11R-1915-07 | — | — | 0.856 |
| 2 | SRR25043621 | — | — | 0.837 |
| 3 | TCGA-D8-A27H-01A-11R-A16F-07 | — | E | 0.823 |
| 4 | SRR8943032 | — | — | 0.814 |
| 5 | SRR8613779 | — | D | 0.799 |
| 6 | SRR5903555 | — | cohortSQ1 | 0.798 |
| 7 | TCGA-A2-A4RX-01A-11R-A266-07 | — | D | 0.794 |
| 8 | MBCProject_0217_T1_RNA | — | C | 0.792 |
| 9 | TCGA-55-A490-01A-11R-A466-07 | — | cohortA1 | 0.791 |
| 10 | SRR27320698 | — | — | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.520 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |